Meridian Bioscience, Inc.

NasdaqGS:VIVO Voorraadrapport

Marktkapitalisatie: US$1.5b

Meridian Bioscience Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Meridian Bioscience heeft een totaal eigen vermogen van $368.1M en een totale schuld van $25.0M, wat de schuld-eigenvermogensverhouding op 6.8% brengt. De totale activa en totale passiva bedragen respectievelijk $463.1M en $95.0M. De EBIT Meridian Bioscience is $75.6M waardoor de rentedekking 64.5 is. Het heeft contanten en kortetermijnbeleggingen van $81.5M.

Belangrijke informatie

6.8%

Verhouding schuld/eigen vermogen

US$25.00m

Schuld

Rente dekkingsratio64.5x
ContantUS$81.45m
AandelenUS$368.06m
Totaal verplichtingenUS$95.04m
Totaal activaUS$463.10m

Recente financiële gezondheidsupdates

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Meridian Bioscience: High-Probability Merger Arbitrage

Jul 26

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Jul 07

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Jun 27
Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience: Correctly Valued

Jun 26

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09
Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03
Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19
These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10
Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31
Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11
Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24
Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09
Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27
Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $210.6M ) VIVO } overtreffen de korte termijn passiva ( $58.0M ).

Langlopende schulden: De kortetermijnactiva VIVO ( $210.6M ) overtreffen de langetermijnschulden ( $37.1M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: VIVO heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van VIVO is de afgelopen 5 jaar gedaald van 32.2% naar 6.8%.

Schuldendekking: De schuld van VIVO wordt goed gedekt door de operationele kasstroom ( 329.4% ).

Rentedekking: De rentebetalingen op de schuld van VIVO worden goed gedekt door EBIT ( 64.5 x dekking).


Balans


Ontdek gezonde bedrijven